Display options
Cite
Bolen CR, McCord R, Huet S, et al. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017;1(22):1884-1890doi: 10.1182/bloodadvances.2016000786.
Bolen, C. R., McCord, R., Huet, S., Frampton, G. M., Bourgon, R., Jardin, F., Dartigues, P., Punnoose, E. A., Szafer-Glusman, E., Xerri, L., Sujobert, P., Salles, G., & Venstrom, J. M. (2017). Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood advances, 1(22), 1884-1890. https://doi.org/10.1182/bloodadvances.2016000786
Bolen, Christopher R, et al. "Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets." Blood advances vol. 1,22 (2017): 1884-1890. doi: https://doi.org/10.1182/bloodadvances.2016000786
Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, Salles G, Venstrom JM. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10. PMID: 29296835; PMCID: PMC5728140.
Copy Download .nbib Format: NLM
Share it on

Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10.

Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.

Blood advances

Christopher R Bolen, Ronald McCord, Sarah Huet, Garrett M Frampton, Richard Bourgon, Fabrice Jardin, Peggy Dartigues, Elizabeth A Punnoose, Edith Szafer-Glusman, Luc Xerri, Pierre Sujobert, Gilles Salles, Jeffrey M Venstrom

Affiliations

  1. Bioinformatics and.
  2. Oncology Biomarker Development, Genentech, South San Francisco, CA.
  3. Laboratory of Hematology, Lyon-Sud Hospital Center, Pierre-Benite, France.
  4. Cancer Research Center of Lyon, INSERM U1052, Unité Mixte de Recherche Centre National de la Recherche Scientifique 5286, Lyon, France.
  5. Foundation Medicine, Inc, Cambridge, MA.
  6. Henri Becquerel Center, Rouen, France.
  7. Gustave Roussy Institute, Villejuif, France; and.
  8. Department of Bio-Pathology, Hematology, and Tumor Immunology, and.
  9. Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France.

PMID: 29296835 PMCID: PMC5728140 DOI: 10.1182/bloodadvances.2016000786

Abstract

Identifying follicular lymphoma (FL) patients with preexisting antitumor immunity will inform precision medicine strategies for novel cancer immunotherapies. Using clinical and genomic data from 249 FL patients, we determined the clinical impact of mutation load and an effector T-cell (T

Conflict of interest statement

Conflict-of-interest disclosure: C.R.B., R.M., R.B., E.A.P., E.S.-G., and J.M.V. are employed by Genentech and are shareholders in F. Hoffman La Roche. G.M.F. is employed by Foundation Medicine. L.X.

References

  1. Nature. 2014 Nov 27;515(7528):563-7 - PubMed
  2. Lancet. 2016 May 7;387(10031):1909-20 - PubMed
  3. Clin Cancer Res. 2014 Jul 1;20(13):3401-10 - PubMed
  4. Genome Med. 2017 Apr 19;9(1):34 - PubMed
  5. Blood. 2004 Nov 1;104(9):2840-8 - PubMed
  6. Blood. 2015 Jan 1;125(1):82-9 - PubMed
  7. Nature. 2013 Oct 17;502(7471):333-339 - PubMed
  8. Proc Natl Acad Sci U S A. 2015 Mar 10;112(10 ):E1116-25 - PubMed
  9. Oncotarget. 2015 Oct 27;6(33):34221-7 - PubMed
  10. Nature. 2014 Nov 27;515(7528):568-71 - PubMed
  11. Science. 2015 Apr 3;348(6230):124-8 - PubMed
  12. Hum Pathol. 2017 Jun;64:128-136 - PubMed
  13. Blood. 2011 Nov 17;118(20):5371-9 - PubMed
  14. Clin Cancer Res. 2004 Apr 1;10(7):2253-64 - PubMed
  15. Genome Biol. 2014 Feb 03;15(2):R29 - PubMed
  16. Science. 2016 Mar 25;351(6280):1463-9 - PubMed
  17. Blood. 2010 Jan 14;115(2):289-95 - PubMed
  18. N Engl J Med. 2004 Nov 18;351(21):2159-69 - PubMed
  19. Cell. 2015 Jan 15;160(1-2):48-61 - PubMed
  20. Blood. 2009 Apr 16;113(16):3809-12 - PubMed
  21. N Engl J Med. 2014 Dec 4;371(23 ):2189-2199 - PubMed
  22. Nat Med. 2015 Jan;21(1):81-5 - PubMed
  23. Nature. 2017 Jan 18;541(7637):321-330 - PubMed
  24. Clin Cancer Res. 2015 Aug 1;21(15):3428-35 - PubMed
  25. J Clin Oncol. 2016 Mar 10;34(8):833-42 - PubMed
  26. Blood. 2016 Jun 16;127(24):3004-14 - PubMed
  27. Cancer Immunol Res. 2014 Sep;2(9):878-89 - PubMed
  28. Sci Transl Med. 2013 Aug 28;5(200):200ra116 - PubMed
  29. Nat Biotechnol. 2013 Nov;31(11):1023-31 - PubMed
  30. Lancet Oncol. 2014 Jan;15(1):69-77 - PubMed
  31. Nature. 2013 Aug 22;500(7463):415-21 - PubMed
  32. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10972-7 - PubMed
  33. Cancer Res. 2006 Oct 15;66(20):10145-52 - PubMed
  34. Science. 2015 Apr 3;348(6230):69-74 - PubMed
  35. Lancet. 2016 Apr 30;387(10030):1837-46 - PubMed
  36. Nat Methods. 2015 May;12(5):453-7 - PubMed
  37. Lancet. 2011 Jan 1;377(9759):42-51 - PubMed
  38. Nature. 2016 Aug 4;536(7614):91-5 - PubMed
  39. J Clin Oncol. 2003 Nov 1;21(21):3940-7 - PubMed

Publication Types